Tarpeyo (Budesonide) Patent Expiration, LOE Window & CMS Spending

Tarpeyo (Budesonide) by Calliditas Therapeutics Ab: FDA Orange Book LOE 2043-01-23, 5 AB generics, $64.8M 2024 CMS Part D & Medicaid spend, and 2 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorCalliditas Therapeutics Ab
FDA Application & PathwayN215935 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2043-01-23
Orange Book Patents (*PED Extensions)5 patents (0 *PED)
Active AB-Rated Generic Competitors5
2024 CMS Total Public Spend$64.8M
2024 Medicare Part D Spend$38.3M
2024 Medicaid Spend$26.6M
Reported Wholesale Price Change (CA SB 17)2 WAC filings (max 28.7% 2-yr change)